WO2001073104A9 - Beta-glucans from filamentous fungi - Google Patents

Beta-glucans from filamentous fungi

Info

Publication number
WO2001073104A9
WO2001073104A9 PCT/EP2001/003100 EP0103100W WO0173104A9 WO 2001073104 A9 WO2001073104 A9 WO 2001073104A9 EP 0103100 W EP0103100 W EP 0103100W WO 0173104 A9 WO0173104 A9 WO 0173104A9
Authority
WO
WIPO (PCT)
Prior art keywords
beta
glucan
rhizoctonia
penicillium
fungus
Prior art date
Application number
PCT/EP2001/003100
Other languages
French (fr)
Other versions
WO2001073104A1 (en
Inventor
Federico Federici
Maurizio Petruccioli
Den Broek Peter Van
Francesca Stingele
Original Assignee
Nestle Sa
Federico Federici
Maurizio Petruccioli
Den Broek Peter Van
Francesca Stingele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001570819A priority Critical patent/JP2003528619A/en
Priority to AU5221901A priority patent/AU5221901A/en
Priority to BR0109412-2A priority patent/BR0109412A/en
Priority to CA002399287A priority patent/CA2399287A1/en
Priority to AU2001252219A priority patent/AU2001252219B2/en
Priority to EP01925485A priority patent/EP1268839A1/en
Application filed by Nestle Sa, Federico Federici, Maurizio Petruccioli, Den Broek Peter Van, Francesca Stingele filed Critical Nestle Sa
Priority to MXPA02008391A priority patent/MXPA02008391A/en
Publication of WO2001073104A1 publication Critical patent/WO2001073104A1/en
Priority to US10/236,991 priority patent/US20030050279A1/en
Publication of WO2001073104A9 publication Critical patent/WO2001073104A9/en
Priority to US10/395,191 priority patent/US20030186937A1/en
Priority to US11/012,509 priority patent/US20050095686A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P39/00—Processes involving microorganisms of different genera in the same process, simultaneously
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
    • A23L29/271—Curdlan; beta-1-3 glucan; Polysaccharides produced by agrobacterium or alcaligenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Definitions

  • the present invention relates to a method of producing a beta-glucan; use of a non-pathogenic saprophytic filamentous fungus or composition comprising it for providing a beta-glucan and thereby improving food structure, texture, stability or a combination thereof; use of a non-pathogenic saprophytic filamentous fungus for providing a beta-glucan and thereby providing nutrition; and use of a fungus or composition comprising it in the manufacture of a medicament or nutritional composition for the prevention or treatment of an immune disorder, tumour or microbial infection.
  • Beta-glucans are made of a ⁇ - glucose which are linked by 1-3 or 1-6 bonds and have the following characteristics that are attractive to the food-industry: viscosifying, emulsifying, stabilising, cryoprotectant and immune-stimulating activities.
  • fungi can produce high amounts of biopolymers (20 g/1) such as beta-glucans.
  • biopolymers (20 g/1) such as beta-glucans.
  • scleroglucan a polysaccharide produced by certain filamentous fungi (e.g. Sclerotinia,
  • Corticiwn, and Stromatina species which, because of its physical characteristics, has been used as a lubricant and as a pressure-compensating material in oil drilling (Wang, Y., and B. Mc Neil. 1996. Scleroglucan. Critical Reviews in Biotechnology 16: 185-215).
  • Scleroglucan consists of a ⁇ (l-3) linked glucose backbone with different degrees of ⁇ (l-6) glucose side groups. The presence of these side groups increases the solubility and prevents triple helix formation which, by consequence, decreases its ability to form gels.
  • the viscosity of scleroglucan solutions shows high tolerance to pH (pH 1-11), temperature (constant between 10-90°C) and electrolyte change (e.g. 5% NaCl, 5% CaCl 2 ).
  • electrolyte change e.g. 5% NaCl, 5% CaCl 2
  • its applications in the food industry for bodying, suspending, coating and gelling agents have been suggested and strong immune stimulatory, anti-tumour and anti-microbial activities have been reported (Kulicke, W.-M., A. I. Lettau, and H. Thielking. 1997, Correlation between immunological activity, molar mass, and molecular structure of different (l ⁇ 3)- ⁇ -D-glu
  • EPS filamentous fungi
  • the fungal EPS could be incorporated into a health food (e.g. EPS as texturing fat replacer for low-calorie products or new immuno-stimulatory products) or provided alone for example as a food supplement.
  • the present invention provides a method of producing a beta-glucan which comprises fermenting a suspension comprising a non-pathogenic saprophytic filamentous fungus and extracting a beta-glucan from the suspension.
  • the present invention provides use of a non-pathogenic saprophytic filamentous fungus or composition comprising it for providing a
  • SHEET RULE 26 beta-glucan and thereby enhancing food structure, texture, stability or a combination thereof.
  • the invention provides use of a non-pathogenic saprophytic filamentous fungus or composition comprising it for providing a source of a beta-glucan and thereby providing nutrition.
  • the invention provides use of a non-pathogenic saprophytic filamentous fungus or composition comprising it in the manufacture of a medicament or nutritional composition for the prevention or treatment of an immune disorder, tumour or microbial infection.
  • an embodiment of a method of producing a beta-glucan comprises fermenting a non-pathogenic saprophytic filamentous fungus selected from the group which consists of Penicillium chermesinum, Penicillium ochrochloron, Rhizoctonia sp., Phoma sp., or a combination thereof. More preferably, at least three of these fungi are fermented together. More preferably all of these fungi are fermented together.
  • an embodiment of a method of producing a beta-glucan comprises the step of fermenting for at least about 50 hours, more preferably about 80 hours to about 120 hours, even more preferably about 96 hours.
  • a high yield of beta-glucan is produced.
  • an embodiment of a method of producing a beta-glucan comprises the step of fermenting a suspension in a medium comprising a component selected from the group which consists of NaN0 3 , KH 2 P0 4 , MgS0 4 , KC1 and yeast extract. More preferably it comprises at least three of these components. Most preferably it comprises all of these components. It has been found that a medium having these components provides the advantage that a high yield of beta-glucan is produced.
  • an embodiment of a method of producing beta-glucans comprises the step of cultivating the fungus in minimal medium.
  • the medium comprises only glucose and salts and provides the advantage of enabling isolation of a highly pure polysaccharide at the expense of the production yield. This is because yeast extract contains polysaccharides that are difficult to separate from the EPS.
  • the medium comprises NaN0 3 (10 mM), KH 2 P0 4 (1.5 g/1), MgS0 4 (0.5 g/1), KC1 (0.5), C 4 H 12 N 2 0 6 (10 mM) glucose (60) adjusted to pH 4.7.
  • an embodiment of use of a fungus according to an aspect of the invention comprises use of a fungus selected from the group which consists of Penicillium chermesinum, Penicillium ochrochloron, Rhizoctonia sp., Phoma sp., or a combination thereof.
  • a method of producing a beta-glucan comprises fermenting a suspension which comprises a fungus in a medium of (g/1) NaN0 3 (3), KH 2 P0 4 (1), MgS0 4 (0.5), KC1 (0.5), Yeast Extract (1.0), glucose (30) adjusted to pH 4.7.
  • the fermentation is allowed to proceed for about 96 hours at about 28 °C with shaking at about 18rpm.
  • strains which initially do not appear to produce polysaccharide are incubated for about 168 hours.
  • Media TBl (g/1) was used as follows: NaN0 3 (3), KH 2 P0 4 (1), MgS0 4 (0.5), KC1 (0.5), Yeast Extract (1.0), glucose (30) adjusted to pH 4.7
  • Fermentation time was 96 h at 28°C with shaking at 180 rpm.
  • the incubation was prolonged to 168 h.
  • Botritis cinerea P3 2.64 + 0.10 5.90 + 0.57 4.35 2.23
  • Penicillium ochrochloron P45 10.53 ⁇ 2.87 0.45 + 0.07 3.50 0.04
  • urea Besides sodium nitrate, other nitrogen sources such as urea, ammonium nitrate, ammonium phosphate and ammonium sulphate were used.
  • urea EPS production by Rhizoctonia sp. P82 and Phoma sp. P98 reached the same levels obtained on sodium nitrate.
  • EPS PURIFICATION AND CHARACTERIZATION The EPSs produced by Rhizoctonia sp. P82, Phoma sp. P98 and Penicillium chermesinum P28 were purified. The polysaccharides were exclusively constituted of sugars, thus indicating suprisingly high levels of purity. Both thin layer chromatography (TLC) and gas chromatography (GC) analysis showed that the EPSs from Rhizoctonia sp. P82 and Phoma sp. P98 were constituted of glucose only. In contrast, that from P. chermesinum P28 was constituted of galactose with traces of glucose.
  • TLC thin layer chromatography
  • GC gas chromatography
  • the EPSs from Rhizoctonia sp. P82 and Phoma sp. P98 were subjected to in vitro and in vivo experiments.
  • the purified EPSs were randomly broken in fragments of different molecular weights (from 1-10 to MO 4 Da) by sonication. The free glucose concentrations of the sonicated samples did not increase, thus indicating that no branches were broken.
  • the experiments were carried out with EPSs at high MW (HMW, the native EPSs), mmeeddium MW (MMW, around 5-10 5 Da) and low MW (LMW, around 5-10 4 Da).
  • Immuno-stimulatory action was evaluated in vitro by determining effect on TNF- ⁇ production, phagocytosis induction, lymphocytes proliferation and IL- 2 production.
  • EPSs stimulated monocytes to produce TNF- ⁇ factor; its content increased with increased polysaccharide concentration and was maximum when medium and low MWs were used.
  • mice Female mice were inoculated three times subcutaneously (SC) and/or orally (OR) with MMW EPS (2 mg/100 g weight) and Lactobacillus acidophilus (MO 8 cells/100 g weight) after 1, 8 and 28 days. Bleedings were carried out after 13 and 33 days. In vivo immuno-stimulation was evaluated by comparing antibody production by an ELISA test.
  • mice that received OR bacteria showed no increase in their antibody content, regardless of their glucan inoculation. However, differences in antibody production were observed among mice inoculated SC with bacteria. Furthermore, antibody levels of mice that received SC only bacteria were significantly higher (P ⁇ 0.01, by Tukey Test) than those that had received glucan and bacteria both SC and glucan OR and bacteria SC.
  • Rhizoctonia sp P82 is interesting in view of its short time required for fermentation, its high level of EPS production and its absence of ⁇ -glucanase activity during the EPS production phase.
  • its EPS, as well as that from Phoma sp. P98 is a glucan characterised by ⁇ -1,3 and ⁇ -1,6 linkages.
  • results relating to immuno-stimulatory effects of the glucan produced by Rhizoctonia sp. P82 indicate the possibility of a good stimulatory activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method of producing a beta-glucan; use of a non-pathogenic saprophytic filamentous fungus or composition comprising it for providing a beta-glucan and thereby improving food structure, texture, stability or a combination thereof; use of a non-pathogenic saprophytic filamentous fungus for providing a beta-glucan and thereby providing nutrition; and use of a fungus or composition comprising it in the manufacture of a medicament or nutritional composition for the prevention or treatment of an immune disorder, tumour or microbial infection.

Description

Beta-glucans
The present invention relates to a method of producing a beta-glucan; use of a non-pathogenic saprophytic filamentous fungus or composition comprising it for providing a beta-glucan and thereby improving food structure, texture, stability or a combination thereof; use of a non-pathogenic saprophytic filamentous fungus for providing a beta-glucan and thereby providing nutrition; and use of a fungus or composition comprising it in the manufacture of a medicament or nutritional composition for the prevention or treatment of an immune disorder, tumour or microbial infection.
Within the context of this specification the word "comprises" is taken to mean "includes, among other things". It is not intended to be construed as "consists of only".
Over the last decade there has been a great deal of interest in biopolymers from microbial origins in order to replace traditional plant- and animal derived gums in nutritional compositions. New biopolymers could lead to the development of materials with novel, desirable characteristics that could be more easily produced and purified. For this reason, characterisation of exopolysaccharide (EPS) production at a biochemical as well as at a genetic level has been studied. An advantage of EPS is that they can be secreted by food micro-organisms during fermentation, however, using EPS produced by micro-organisms gives rise to the problem that the level of production is very low (50-500 mg/1) and that once the EPS is extracted it loses its texturing properties.
One example of an EPS is a beta-glucan. Beta-glucans are made of a β- glucose which are linked by 1-3 or 1-6 bonds and have the following characteristics that are attractive to the food-industry: viscosifying, emulsifying, stabilising, cryoprotectant and immune-stimulating activities.
Remarkably, it has been found that fungi can produce high amounts of biopolymers (20 g/1) such as beta-glucans. One example is scleroglucan, a polysaccharide produced by certain filamentous fungi (e.g. Sclerotinia,
Corticiwn, and Stromatina species) '- which, because of its physical characteristics, has been used as a lubricant and as a pressure-compensating material in oil drilling (Wang, Y., and B. Mc Neil. 1996. Scleroglucan. Critical Reviews in Biotechnology 16: 185-215).
Scleroglucan consists of a β(l-3) linked glucose backbone with different degrees of β(l-6) glucose side groups. The presence of these side groups increases the solubility and prevents triple helix formation which, by consequence, decreases its ability to form gels. The viscosity of scleroglucan solutions shows high tolerance to pH (pH 1-11), temperature (constant between 10-90°C) and electrolyte change (e.g. 5% NaCl, 5% CaCl2). Furthermore, its applications in the food industry for bodying, suspending, coating and gelling agents have been suggested and strong immune stimulatory, anti-tumour and anti-microbial activities have been reported (Kulicke, W.-M., A. I. Lettau, and H. Thielking. 1997, Correlation between immunological activity, molar mass, and molecular structure of different (l→3)-β-D-glucans. Carbohydr. Res. 297: 135-143).
Remarkably, a class of filamentous fungi has now been identified and isolated which has been found to produce a fungal exopolysaccharide that exhibits characteristics that are attractive to the food industry. Two aspects of the EPS of interest are (a) its good texturing properties and (b) its ability to promote an immuno-stimulatory effect in in vitro and in vivo immunological assays. The fungal EPS could be incorporated into a health food (e.g. EPS as texturing fat replacer for low-calorie products or new immuno-stimulatory products) or provided alone for example as a food supplement.
Surprisingly, it has been found that these fungi are able to produce a remarkably high yield of a beta-glucan.
Accordingly, in a first aspect the present invention provides a method of producing a beta-glucan which comprises fermenting a suspension comprising a non-pathogenic saprophytic filamentous fungus and extracting a beta-glucan from the suspension.
In a second aspect the present invention provides use of a non-pathogenic saprophytic filamentous fungus or composition comprising it for providing a
SHEET RULE 26 beta-glucan and thereby enhancing food structure, texture, stability or a combination thereof.
In a third aspect the invention provides use of a non-pathogenic saprophytic filamentous fungus or composition comprising it for providing a source of a beta-glucan and thereby providing nutrition.
In a forth aspect the invention provides use of a non-pathogenic saprophytic filamentous fungus or composition comprising it in the manufacture of a medicament or nutritional composition for the prevention or treatment of an immune disorder, tumour or microbial infection.
Preferably, an embodiment of a method of producing a beta-glucan comprises fermenting a non-pathogenic saprophytic filamentous fungus selected from the group which consists of Penicillium chermesinum, Penicillium ochrochloron, Rhizoctonia sp., Phoma sp., or a combination thereof. More preferably, at least three of these fungi are fermented together. More preferably all of these fungi are fermented together.
Preferably, an embodiment of a method of producing a beta-glucan comprises the step of fermenting for at least about 50 hours, more preferably about 80 hours to about 120 hours, even more preferably about 96 hours. Remarkably, it has now been found that if fermentation is carried out for this time, it provides the advantage that a high yield of beta-glucan is produced.
Preferably, an embodiment of a method of producing a beta-glucan comprises the step of fermenting a suspension in a medium comprising a component selected from the group which consists of NaN03, KH2P04, MgS04, KC1 and yeast extract. More preferably it comprises at least three of these components. Most preferably it comprises all of these components. It has been found that a medium having these components provides the advantage that a high yield of beta-glucan is produced.
Preferably, an embodiment of a method of producing beta-glucans comprises the step of cultivating the fungus in minimal medium. Preferably, the medium comprises only glucose and salts and provides the advantage of enabling isolation of a highly pure polysaccharide at the expense of the production yield. This is because yeast extract contains polysaccharides that are difficult to separate from the EPS. Most preferably the medium comprises NaN03 (10 mM), KH2P04 (1.5 g/1), MgS04 (0.5 g/1), KC1 (0.5), C4H12N206 (10 mM) glucose (60) adjusted to pH 4.7.
Preferably, an embodiment of use of a fungus according to an aspect of the invention comprises use of a fungus selected from the group which consists of Penicillium chermesinum, Penicillium ochrochloron, Rhizoctonia sp., Phoma sp., or a combination thereof.
Additional features and advantages of the present invention are described in, and will be apparent from the description of the presently preferred embodiments which are set out below.
In an embodiment, a method of producing a beta-glucan comprises fermenting a suspension which comprises a fungus in a medium of (g/1) NaN03 (3), KH2P04 (1), MgS04 (0.5), KC1 (0.5), Yeast Extract (1.0), glucose (30) adjusted to pH 4.7. The fermentation is allowed to proceed for about 96 hours at about 28 °C with shaking at about 18rpm. In an alternative embodiment, strains which initially do not appear to produce polysaccharide are incubated for about 168 hours.
The following examples are given by way of illustration only and in no way should be construed as limiting the subject matter of the present application.
Example 1:
FUNGAL BETA-GLUCAN PRODUCTION:
The following fungal isolates were isolated and classified:
Figure imgf000005_0001
Figure imgf000006_0001
** anamorph = asexual form, * teleomorph= sexual form N/A = not available.
Example 2
STANDARDPOLYSACCHARIDEPRODUCTION
Media TBl (g/1) was used as follows: NaN03 (3), KH2P04 (1), MgS04 (0.5), KC1 (0.5), Yeast Extract (1.0), glucose (30) adjusted to pH 4.7
Fermentation time was 96 h at 28°C with shaking at 180 rpm. For strains which initially did not seem to produce any polysaccharide the incubation was prolonged to 168 h.
Results of polysaccharide production were as follows:
Fungal strain Biomass Polysaccharide pH Specific
(g/i) (g/i) production (g/g)
Slerotium glucanicum NRRL 9.06 + 2.06 11.20 + 0.71 3.79 1.24
3006
Botritis cinerea P3 2.64 + 0.10 5.90 + 0.57 4.35 2.23
Sclerotinia sclerotiorum P4 1.16 + 0.16 1.61 + 0.13 2.50 1.38
Fusarium culmorum P8 6.51 + 1.05 0.82 ± 0.13 7.70 0.13
Not identified P9 5.43 + 0.53 1.32 + 0.02 4.00 0.24
Penicillium chermesinum P28 4.08 ± 1.17 0.68 + 0.11 3.30 0.17
Penicillium ochrochloron P45 10.53 ± 2.87 0.45 + 0.07 3.50 0.04
Fusarium sp. P58 8.60 + 2.12 1.25 + 0.35 7.44 0.15 Sclerotinia sclerotiorum P62 2.10 + 0.00 0.86 + 0.00 3.80 0.41 Sclerotinia sclerotiorum P63 4.08 + 0.54 1.33 + 0.04 3.30 0.33 Botritis fabae P65 19.70 + 0.00 0.50 + 0.00 4.94 0.03 Rhizoctonia fragariae P70 12.52 + 0.40 1.55 + 0.07 8.60 0.12 Colletotrichum acutatum P72 6.01 + 0.89 1.05 + 0.07 7.00 0.17 Pestalotia sp. P75 8.70 + 0.28 1.90 + 0.28 6.30 0.22 Colletotrichum sp. P80 12.00 + 1.95 0.65 + 0.07 6.50 0.05 Colletotrichum sp. P81 5.10 + 0.71 0.80 + 0.00 5.70 0.16 Rhizoctonia sp. P82 5.70 + 0.28 8.90 + 1.56 6.50 1.56 Acremonium sp. P83 4.69 + 0.62 1.45 + 0.07 7.20 0.31 Acremonium sp. P84 5.50 + 0.00 1.30 + 0.00 7.20 0.24 Acremonium sp. P86 3.90 + 0.71 1.00 + 0.14 5.85 0.26 Acremonium sp. P90 8.08 + 0.01 0.73 + 0.18 4.40 0.09 Not identified P91 10.50 + 0.14 1.28 + 0.31 6.83 0.12 Chaetomium sp. P94 8.30 + 1.43 1.00 + 0.28 7.40 0.12 Phoma herbarum P97 13.61 + 2.34 0.98 + 0.22 7.50 0.07 Phoma sp. P98 11.01 + 1.07 2.89 + 0.01 8.00 0.26 Phoma sp. P99 11.76 + 1.66 0.66 + 0.04 6.45 0.06
*Values are given at the time of maximum EPS production. Data are means of two independent experiments ±standard deviation.
Example 3
OPTIMIZED POLYSACCHARDE PRODUCTION
Polysaccharide production by Rhizoctonia sp. P82, Phoma sp. P98 and Penicillium chermesinum P28 were studied. The results were as follows:
A. Effect of carbon source cultivated on TB 1 : I. EPS production by Rhizoctonia sp. P82
Carbon source** Biomass Polysaccharide PH Specific
(g/i) (g/i) production (g/g)
Glucose 3.74 + 0.80 18.55 + 0.57 5.48 4.96
Fructose 4.20 + 0.58 21.10 + 0.89 5.60 5.02
Galactose 4.21 + 0.19 16.67 + 1.20 6.52 3.96 Xylose 3.45 + 0.53 15.94 + 2.42 6.07 4.63
Sorbitol 5.19 + 0.80 4.70 ± 0.21 6.16 0.91
Glycerol 5.25 + 0.60 1.54 + 0.42 6.15 0.29
Sucrose 4.03 + 0.59 14.07 + 0.64 5.61 3.49
Maltose 4.07 + 0.32 12.22 + 0.34 5.28 3.00
Lactose 4.63 + 0.47 8.78 + 0.59 6.34 1.90
Starch 5.77 + 0.95 17.36 + 0.69 6.26 3.01
*Values are given at the time of maximum EPS production. Data are means of three independent experiments ± standard deviation. ** Carbon sources were added to the medium at 30 g/1.
II. EPS production by Phoma sp. P98.
Carbon source** Biomass Polysaccharide PH Specific
(g/i) (g/i) production (g/g)
Glucose 11.99 + 0.64 1.97 ± 1.22 7.31 0.16
Fructose 11.11 + 0.76 1.22 ± 0.45 7.35 0.11
Galactose 10.35 + 0.78 4.12 ± 0.03 7.44 0.40
Xylose 11.47 + 1.40 2.57 + 0.27 7.35 0.22
Sorbitol 11.17 + 0.69 7.54 ± 1.10 7.10 0.68
Glycerol 11.00 + 0.37 0.63 ± 0.05 7.29 0.06
Sucrose 12.93 + 0.44 2.91 + 0.55 7.36 0.23
Maltose 12.50 + 0.18 2.65 + 0.98 6.92 0.21
Lactose 9.77 + 0.01 1,06 + 0.14 7.05 0.11
Starch 13.51 + 1.65 2.28 ± 0.11 7.43 0.17
*Values are given at the time of maximum EPS production. Data are means of three independent experiments ± standard deviation. ** Carbon sources were added to the medium at 30 g/1.
III. EPS production by Penicillium chermesinum P28:i
Carbon source** Biomass Polysaccharide PH Specific
(g/i) (g/i) production
(g/g)
Glucose 11.69 + 0.04 0.59 + 0.13 3.51 0.05
Fructose 12.91 ± 1.20 0.46 + 0.06 3.64 0.04
Galactose 8.64 ± 2.09 0.00 + 0.00 5.23 0.00 Xylose 10.68 ± 0.06 0.41 + 0.13 3.57 0.04
Sorbitol 8.58 ± 1.67 1.09 ± 0.01 5.07 0.13
Glycerol 13.06 + 1.05 0.18 + 0.04 3.57 0.01
Sucrose 13.11 + 0.80 0.59 + 0.11 3.44 0.05
Maltose 10.90 + 1.11 0.61 + 0.16 3.53 0.06
Lactose 9.38 + 0.34 0.00 + 0.00 4.69 0.00
Starch 9.92 + 2.04 0.50 ± 0.05 3.58 0.05
*Values are given at the time of maximum EPS production. Data are means of three independent experiments ± standard deviation. ** Carbon sources were added to the medium at 30 g/1.
B. Effect of glucose concentration cultivated on TBl: I. EPS production by Rhizoctonia sp. P82*.
Glucose Biomass Polysaccharide pH Specific
(g/i) (g/i) (g/i) production (g/g)
30 3.74 + 0.80 18.55 + 0.57 5.85 4.96
40 7.29 + 0.42 21.40 + 0.89 6.03 2.94
50 8.30 + 0.74 30.20 + 1.47 5.67 3.64
60 8.17 ± 1.34 35.26 + 1.64 6.13 4.32
*Values are given at the time of maximum EPS production. Data are means of three independent experiments ± standard deviation.
II. EPS production by Phoma sp. P98* .
Sorbitol Biomass Polysaccharide pH Specific
(g/i) (g/i) (g/i) production (g/g)
30 8.60 + 0.88 5.78 + 0.61 7.22 0.67
40 12.08 + 0.71 8.76 + 0.40 7.12 0.73
50 13.22 + 1.43 10.70 + 0.48 7.13 0.81
60 16.47 + 0.21 13.11 + 0.33 7.56 0.80
Suprisingly, it can be seen from the results that increasing the concentration of the carbon source (glucose and sorbitol for Rhizoctonia sp. P82 and Phoma sp. P98, respectively), EPS production by both strains increased markedly (approx. 100% increase) reaching a maximum of 35.2 and 13.1 g/1, respectively.
C. Effect of nitrogen source cultivated on TBl: I. EPS production by Rhizoctonia sp. P82.
Nitrogen Biomass Polysaccharide PH Specific source (g/i) (g/i) production (g/g)
NaNOs 3.74 + 0.80 18.55 + 0.57 5.53 4.96
NH4N03 4.05 ± 0.29 13.07 + 1.87 2.58 3.23
Urea 5.54 ± 0.35 21.20 + 0.14 5.43 3.82
(NH4)2HP04 3.09 + 0.81 14.26 + 0.52 2.44 4.61
(NH4)2S04 2.39 + 0.49 8.91 ± 0.58 2.23 3.73
*Values are given at the time of maximum EPS production. Data are means of three independent experiments ± standard deviation.
II. EPS production by Phoma sp. P98.
Nitrogen Biomass Polysaccharide PH Specific source (g/i) (g/i) production
(g/g)
NaN03 11.46 + 0.85 3.24 ± 0.63 7.22 0.28
NH4N03 6.12 ± 0.33 1.17 + 0.43 2.33 0.19
Urea 8.09 + 1.01 3.57 + 0.97 6.18 0.44
(NH4)2HP04 6.53 + 0.44 0.00 ± 0.00 2.43 0.00 *Values are given at the time of maximum EPS production. Data are means of three independent experiments ± standard deviation.
Besides sodium nitrate, other nitrogen sources such as urea, ammonium nitrate, ammonium phosphate and ammonium sulphate were used. Remarkably, on urea, EPS production by Rhizoctonia sp. P82 and Phoma sp. P98 reached the same levels obtained on sodium nitrate.
Example 4
EPS PURIFICATION AND CHARACTERIZATION The EPSs produced by Rhizoctonia sp. P82, Phoma sp. P98 and Penicillium chermesinum P28 were purified. The polysaccharides were exclusively constituted of sugars, thus indicating suprisingly high levels of purity. Both thin layer chromatography (TLC) and gas chromatography (GC) analysis showed that the EPSs from Rhizoctonia sp. P82 and Phoma sp. P98 were constituted of glucose only. In contrast, that from P. chermesinum P28 was constituted of galactose with traces of glucose.
The molecular weights (MW) of the EPSs from Rhizoctonia sp. and Phoma sp., estimated by gel permeation chromatography using a 100x1 cm Sepharose CL4B gel (Sigma) column, were both approximately 2-10 Da.
Determination of the position of the glucosidic linkages in the EPSs from Rhizoctonia sp. P82 and Phoma sp. P98 was carried out by GCms and GC after methylation, total hydrolysis, reduction and acetylation. The main products were identified by GCms analysis as glucitol 2,4-di-O-methyl- tetracetylated, glucitol 2,4,6-tri-O-methyl-triacetylated and glucitol 2,3,4,6- tetra-O-methyl-diacetylated indicating that both EPSs were characterised by monosaccharides linked with β-1,3 and β-1,6 linkages. In the case of the EPS from Phoma sp., the GC analyses showed three peaks in a quantitative ratio typical of a glucan with many branches; besides the above reaction products, the same type of analysis showed that the EPS from Rhizoctonia sp. gave rise to other reaction products such as penta- and esa-O-methyl-acetylated compounds which clearly indicated an uncompleted methylation.
Surprisingly, NMR analysis confirmed that both polysaccharides were pure, constituted of glucose only and characterised by β-1,3 and β-1,6 linkages.
Example 5
EPS IMMUNO-STIMULATORY EFFECTS
The EPSs from Rhizoctonia sp. P82 and Phoma sp. P98 were subjected to in vitro and in vivo experiments. A purified scleroglucan, obtained from S. glucanicum NRRL 3006, was used as a control. The purified EPSs were randomly broken in fragments of different molecular weights (from 1-10 to MO4 Da) by sonication. The free glucose concentrations of the sonicated samples did not increase, thus indicating that no branches were broken. The experiments were carried out with EPSs at high MW (HMW, the native EPSs), mmeeddium MW (MMW, around 5-105 Da) and low MW (LMW, around 5-104 Da).
Immuno-stimulatory action was evaluated in vitro by determining effect on TNF-α production, phagocytosis induction, lymphocytes proliferation and IL- 2 production.
All the EPSs stimulated monocytes to produce TNF-α factor; its content increased with increased polysaccharide concentration and was maximum when medium and low MWs were used.
In order to assess the effect of the EPSs on phagocytosis, two methods (Phagotest and Microfluoimetric Phagocytosis Assay) were used. The results gave a good indication that a high concentration of EPS improves phagocytosis.
In contrast, no significant effects were observed on lymphocyte proliferation and IL-2 production when the EPSs were added either alone or in combination with phytohemagglutinin (PHA). In addition, no cytotoxic effects were observed.
An in vivo study was carried out to assess immuno-stimulatory activity of the EPS using MMW (around 5-105 Da) glucan from Rhizoctonia sp. P82.
Female mice were inoculated three times subcutaneously (SC) and/or orally (OR) with MMW EPS (2 mg/100 g weight) and Lactobacillus acidophilus (MO8 cells/100 g weight) after 1, 8 and 28 days. Bleedings were carried out after 13 and 33 days. In vivo immuno-stimulation was evaluated by comparing antibody production by an ELISA test.
All the mice that received OR bacteria (groups 3, 4 and 5) showed no increase in their antibody content, regardless of their glucan inoculation. However, differences in antibody production were observed among mice inoculated SC with bacteria. Furthermore, antibody levels of mice that received SC only bacteria were significantly higher (P<0.01, by Tukey Test) than those that had received glucan and bacteria both SC and glucan OR and bacteria SC.
Interestingly, the results indicate that the EPS from Rhizoctonia sp. Gives rise to a decrease in antibody concentration. Remarkably, it can be concluded from this that the glucan from Rhizoctonia sp. causes activation of an antimicrobial activity of monocytes (see the effects described above relating to TNF-α production and phagocytosis induction) with a consequent reduction in the bacterial number leading, in turn, to a consistent reduction in antibody production.
In conclusion, the three filamentous fungi Rhizoctonia sp P82, Phoma sp. P98 and Penicillium chermesinum P28 have a suprisingly good ability to produce extracellular polysaccharides of potential interest. In particular, Rhizoctonia sp. P82 is interesting in view of its short time required for fermentation, its high level of EPS production and its absence of β-glucanase activity during the EPS production phase. Furthermore, its EPS, as well as that from Phoma sp. P98, is a glucan characterised by β-1,3 and β-1,6 linkages. In addition, results relating to immuno-stimulatory effects of the glucan produced by Rhizoctonia sp. P82 indicate the possibility of a good stimulatory activity.
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

Claims

Claims
1. A method of producing a beta-glucan which comprises fermenting a suspension comprising a non-pathogenic saprophytic filamentous fungus and extracting a beta-glucan from the suspension.
2. A method according to claim 1 wherein the non-pathogenic saprophytic filamentous fungus is selected from the group which consists of Penicillium chermesinum, Penicillium ochrochloron, Rhizoctonia sp., Phoma sp., or a combination thereof.
3. A method according to claim 1 or 2 wherein the non-pathogenic saprophytic filamentous fungi Penicillium chermesinum, Penicillium ochrochloron, Rhizoctonia sp. and Phoma sp. are fermented together.
A method according to any preceding claim wherein the step of fermentation is carried out for at least about 50 hours.
5. A method according to any preceding claim wherein the step of fermenting is carried out in a medium comprising a component selected from the group which consists of NaN03, KH2P04, MgS04, KC1 and yeast extract.
6. A method according to any preceding claim wherein the step of fermenting is carried out by cultivating the fungus in minimal medium which comprises only glucose and salts.
7. A method according to any preceding claim wherein the step of fermenting is carried out by cultivating the fungus in a medium which comprises NaN03 (10 mM), KH2P04 (1.5 g/1), MgS04 (0.5 g/1), KC1 (0.5), C4Hι2N206 (10 mM) glucose (60) adjusted to pH 4.7.
8. Use of a non-pathogenic saprophytic filamentous fungus or composition comprising it for providing a beta-glucan and thereby enhancing food structure, texture, stability or a combination thereof.
9. Use of a non-pathogenic saprophytic filamentous fungus or composition comprising it for providing a source of a beta-glucan and thereby providing nutrition.
10. Use of a non-pathogenic saprophytic filamentous fungus or composition comprising it in the manufacture of a medicament or nutritional composition for the prevention or treatment of an immune disorder, tumour or microbial infection.
11 , Use according to any one of claims 8 to 10 wherein the non-pathogenic saprophytic filamentous fungus is selected from the group which consists of Penicillium chermesinum, Penicillium ochrochloron, Rhizoctonia sp., Phoma sp., or a combination thereof,
12. Use according to any one of claims 8 to 11 wherein the fungus comprises a combination of Penicillium chermesinum, Penicillium ochrochloron, Rhizoctonia sp. and Phoma sp..
PCT/EP2001/003100 2000-03-24 2001-03-20 Beta-glucans from filamentous fungi WO2001073104A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU5221901A AU5221901A (en) 2000-03-24 2001-03-20 Beta-glucans from filamentous fungi
BR0109412-2A BR0109412A (en) 2000-03-24 2001-03-20 Beta-glycans of filamentous fungi
CA002399287A CA2399287A1 (en) 2000-03-24 2001-03-20 Beta-glucans from filamentous fungi
AU2001252219A AU2001252219B2 (en) 2000-03-24 2001-03-20 Beta-glucans from filamentous fungi
EP01925485A EP1268839A1 (en) 2000-03-24 2001-03-20 Beta-glucans from filamentous fungi
JP2001570819A JP2003528619A (en) 2000-03-24 2001-03-20 Β-glucan derived from filamentous fungi
MXPA02008391A MXPA02008391A (en) 2000-03-24 2001-03-20 Beta glucans from filamentous fungi.
US10/236,991 US20030050279A1 (en) 2000-03-24 2002-09-05 Beta-glucans
US10/395,191 US20030186937A1 (en) 2000-03-24 2003-03-25 Beta-glucans
US11/012,509 US20050095686A1 (en) 2000-03-24 2004-12-14 Beta-glucans

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00106406.2 2000-03-24
EP00106406 2000-03-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/236,991 Continuation US20030050279A1 (en) 2000-03-24 2002-09-05 Beta-glucans

Publications (2)

Publication Number Publication Date
WO2001073104A1 WO2001073104A1 (en) 2001-10-04
WO2001073104A9 true WO2001073104A9 (en) 2003-03-20

Family

ID=8168221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003100 WO2001073104A1 (en) 2000-03-24 2001-03-20 Beta-glucans from filamentous fungi

Country Status (10)

Country Link
US (3) US20030050279A1 (en)
EP (1) EP1268839A1 (en)
JP (1) JP2003528619A (en)
CN (1) CN1418256A (en)
AU (2) AU2001252219B2 (en)
BR (1) BR0109412A (en)
CA (1) CA2399287A1 (en)
MX (1) MXPA02008391A (en)
WO (1) WO2001073104A1 (en)
ZA (1) ZA200208590B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923437B2 (en) * 2001-02-16 2011-04-12 Cargill, Incorporated Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
US8222232B2 (en) * 2001-02-16 2012-07-17 Cargill, Incorporated Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass
US7816514B2 (en) 2001-02-16 2010-10-19 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
FR2887750B1 (en) * 2005-07-04 2008-07-04 Kitozyme Sa USE OF FUNGAL BIOMASS EXTRACT AS A TECHNOLOGICAL AUXILIARY FOR THE TREATMENT OF FOOD FLUIDS
JP2008142577A (en) * 2006-12-05 2008-06-26 National Institute Of Advanced Industrial & Technology Method for treating waste liquid in presence of starch fermented material and chemical agent used therein
BRPI0605178A (en) * 2006-12-05 2008-07-22 Univ Estadual Londrina Production process of beta-glucan botriosferan by fermentation and its antimutagenic and hypoglycemic properties
CA2714793A1 (en) * 2008-02-14 2009-08-20 Barley & Oats Co., Ltd. Method for producing fermented product using natural material, and food or medicine containing fermented product made from same
CN102127171B (en) * 2010-12-27 2012-08-22 河北鑫合生物化工有限公司 Method for extracting scleroglucan from scleroglucan fermentation liquid
CN102757902A (en) * 2012-07-20 2012-10-31 江苏苏净集团有限公司 Filamentous fungus culture medium, method for preparing same, and method for culturing filamentous fungi utilizing culture medium
CN109762858B (en) * 2019-03-25 2022-05-31 河北鑫合生物化工有限公司 Method for producing scleroglucan fermentation liquor by taking athelia rolfsii as strain

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301848A (en) * 1962-10-30 1967-01-31 Pillsbury Co Polysaccharides and methods for production thereof
US3987166A (en) * 1970-05-13 1976-10-19 Kaken Kagaku Kabushiki Kaisha Treatment of tumors with glucan compositions in mice and rats
US3943247A (en) * 1972-05-22 1976-03-09 Kaken Kagaku Kabushiki Kaisha Treatment of bacterial infections with glucan compositions
US4537858A (en) * 1984-06-22 1985-08-27 E. R. Squibb & Sons, Inc. Plastatin
FR2631829B1 (en) * 1988-05-30 1992-04-03 Pasteur Institut FUNGAL EXOPOLYSACCHARIDES HAVING IMMUNOSTIMULANT ACTIVITY, PROCESS FOR OBTAINING SAME AND THERAPEUTIC COMPOSITION CONTAINING THEM
US4954440A (en) * 1988-06-16 1990-09-04 The Standard Oil Company Production of polysaccharides from filamentous fungi
US4962094A (en) * 1988-10-28 1990-10-09 Alpha Beta Technology, Inc. Glucan dietary additives
CA2112776C (en) * 1993-01-21 2002-11-12 Masakazu Tsuchiya Process for inhibiting activity of endotoxin
RU2040932C1 (en) * 1993-12-17 1995-08-09 Крестьянское хозяйство "Агрофирма Дижа" Preparation influencing tissular metabolism and application of fusarium sambucinum fuckel var ossicolum (berkiet curf) bilai fungus strain to produce the preparation
JP2746532B2 (en) * 1994-02-23 1998-05-06 宮 和男 Immunity-enhanced foods based on Isaria-type insects
JPH10276740A (en) * 1997-04-09 1998-10-20 Hiroshi Hattori Production of food and beverage containing beta-1,3-1,6-glucan
US6251877B1 (en) * 1998-03-24 2001-06-26 Pacific Corporation Composition for external application containing a β-1,6-branched-β-1,3-glucan

Also Published As

Publication number Publication date
CA2399287A1 (en) 2001-10-04
AU5221901A (en) 2001-10-08
MXPA02008391A (en) 2002-12-13
AU2001252219B2 (en) 2006-02-09
CN1418256A (en) 2003-05-14
WO2001073104A1 (en) 2001-10-04
BR0109412A (en) 2002-12-10
US20030186937A1 (en) 2003-10-02
EP1268839A1 (en) 2003-01-02
JP2003528619A (en) 2003-09-30
ZA200208590B (en) 2004-02-10
US20050095686A1 (en) 2005-05-05
US20030050279A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
Dalonso et al. β-(1→ 3),(1→ 6)-Glucans: medicinal activities, characterization, biosynthesis and new horizons
Lecointe et al. Polysaccharides cell wall architecture of mucorales
Kim et al. Immunostimulatory activities of polysaccharides from liquid culture of pine-mushroom Tricholoma matsutake
Murosaki et al. Immunopotentiating activity of nigerooligosaccharides for the T helper 1-like immune response in mice
Choma et al. Chemical characterization of a water insoluble (1→ 3)-α-D-glucan from an alkaline extract of Aspergillus wentii
US6956120B2 (en) β-1.3-1.6 glucan (Aureobasidium medium)
Harada et al. Curdlan and succinoglycan
Gientka et al. Exopolysaccharides from yeast: insight into optimal conditions for biosynthesis, chemical composition and functional properties? review
Lee et al. Molecular mechanism of macrophage activation by exopolysaccharides from liquid culture of Lentinus edodes
AU2001252219B2 (en) Beta-glucans from filamentous fungi
AU2001252219A1 (en) Beta-glucans from filamentous fungi
Llauradó et al. In-vitro antimicrobial activity and complement/macrophage stimulating effects of a hot-water extract from mycelium of the oyster mushroom Pleurotus sp.
Javmen et al. β-Glucan from Saccharomyces cerevisiae induces IFN-γ production in vivo in BALB/c mice
Jaros et al. Exopolysaccharides from Basidiomycota: Formation, isolation and techno‐functional properties
Catalli et al. Chitin and β-glucan polysaccharides as immunomodulators of airway inflammation and atopic disease
Kojima et al. Structural analysis of glycogen-like polysaccharides having macrophage-activating activity in extracts of Lentinula edodes mycelia
JP4595074B2 (en) Novel glucan and method for producing the same
US11130976B2 (en) Method for preparing high productivity mushroom beta-glucan and products thereof
AU642804B2 (en) Preventive agent against infectious disease of crustacea
US3396082A (en) Glucan production by fermentation of fleshy fungi
Van Bogaert et al. Extracellular polysaccharides produced by yeasts and yeast-like fungi
Masuda et al. Macrophage J774. 1 cell is activated by MZ-Fraction (Klasma-MZ) polysaccharide in Grifola frondosa
Utama et al. Microorganism-based β-glucan production and their potential as antioxidant
Bimczok et al. Short chain regioselectively hydrolyzed scleroglucans induce maturation of porcine dendritic cells
De Oliva-Neto et al. Yeasts as potential source for prebiotic β-glucan: Role in human nutrition and health

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001925485

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2399287

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/008391

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001252219

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10236991

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 018068626

Country of ref document: CN

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 570819

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2002/08590

Country of ref document: ZA

Ref document number: 200208590

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2001925485

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGE 14, CLAIMS, ADDED

WWG Wipo information: grant in national office

Ref document number: 2001252219

Country of ref document: AU